Clinicopathologic Significance of the Mutations of the<i>Epidermal Growth Factor Receptor</i>Gene in Patients with Non–Small Cell Lung Cancer

Yoshio Tomizawa, Hironobu Iijima, Noriaki Sunaga, +11

Clinical Cancer Research

Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy

Noriaki Sunaga, Yoshio Tomizawa, Noriko Yanagitani, +10

Lung Cancer

OncologyPrevious ChemotherapyPathologyBronchial NeoplasmCancer Treatment +4

Expression of L-type amino acid transporter 1 (LAT1) in neuroendocrine tumors of the lung

Kyoichi Kaira, Noboru Oriuchi, Hisao Imai, +11

Pathology - Research and Practice

Oncogenic AgentMedicinePathologyBronchial NeoplasmNeuroendocrine Tumors +4

Epigenetic inactivation of the RUNX3 gene in lung cancer

Koji Sato, Yoshio Tomizawa, Hironobu Iijima, +4

Oncology Reports

Clinicopathological significance of aberrant methylation of RARβ2 at 3p24, RASSF1A at 3p21.3, and FHIT at 3p14.2 in patients with non-small cell lung cancer

Yoshio Tomizawa, Hironobu Iijima, Taisuke Nomoto, +7

Lung Cancer

Tumor BiologyAberrant MethylationClinicopathological SignificanceMedicinePathology +9

A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer

Kyoichi Kaira, Noriaki Sunaga, Yoshio Tomizawa, +13

Lung Cancer

OncologyHealth SciencesMedicineSynthetic 9-AminoanthracyclinePhase Ii Study +9

Genetic and epigenetic inactivation of <i>LTF</i> gene at 3p21.3 in lung cancers

Hironobu Iijima, Yoshio Tomizawa, Yasuki Iwasaki, +7

International Journal of Cancer

Epigenetic Inactivation of the Thyroid Hormone Receptor β1 Gene at 3p24.2 in Lung Cancer

Yasuki Iwasaki, Noriaki Sunaga, Yoshio Tomizawa, +6

Annals of Surgical Oncology

ChromatinMedicineGeneticsEpigenetic InactivationEpigenetic Change +8

Papillary adenocarcinoma of the lung is a more advanced adenocarcinoma than bronchioloalveolar carcinoma that is composed of two distinct histological subtypes

Zhang Jian, Yoshio Tomizawa, Noriko Yanagitani, +3

Pathology International

Phase II study of the efficacy of gefitinib in patients with non-small cell lung cancer with the EGFR mutations

Noriaki Sunaga, Noriko Yanagitani, Kyoichi Kaira, +7

Journal of Clinical Oncology

Cancer ResearchMedicineMetronomic TherapyPathologyPhase Ii Study +12